drug development
Coverage of drug development in the Nexus archive.
- How AI is supercharging drug development
AI is accelerating drug development by reducing preclinical costs and timelines by up to 70%, according to a TD Cowen survey of biopharma leaders. The technology is driving demand for advanced software and computational tools to simulate biological processes and predict drug interactions, though no AI-discovered drug has yet received FDA approval.
- Scientists’ Side Hustle? Using AI and Quantum Computing to Generate New Peptides
Researchers are using AI and quantum computing to develop new peptides for drug development targeting underserved populations and rare diseases. The project combined funding and time to demonstrate quantum computing's potential in this field.
- Claude Science is Anthropic’s newest flagship product
Anthropic announced Claude Science, a new flagship product designed to support scientific research, particularly in computational biology and drug development. The product is now available to paid subscribers and will be used by Anthropic for its own research on rare diseases. The company positions it alongside Claude Code and Claude Cowork, emphasizing its commitment to AI-driven scientific advancements.
- STAT+: Investor Clive Meanwell on designing biotechs for population health, and AI’s role as a catalyst
Clive Meanwell, chairman of Population Health Partners, leveraged a competitive bidding war between Pfizer and Novo Nordisk for obesity startup Metsera, which reached a $10 billion offer. He now focuses on AI-driven solutions to address large-scale health challenges through innovative technologies and business models.
- AstraZeneca CEO says AI is reshaping drug development — and helping boost the odds of success
AstraZeneca CEO Pascal Soriot stated that AI is accelerating drug development and improving decision-making in research. He highlighted AI's role in increasing the likelihood of success for medicine development.